Bafna Pharmaceuticals
136.02
-1.00(-0.73%)
Market Cap₹321.77 Cr
PE Ratio-
IndustryHealthcare
Company Performance:
1D-0.73%
1M+13.68%
6M-1.56%
1Y+83.76%
5Y+5.56%
View Company Insightsright
More news about Bafna Pharmaceuticals
23Jan 26
Bafna Pharmaceuticals Receives Credit Rating Outlook Upgrade from ICRA Limited
Bafna Pharmaceuticals Limited received a credit rating outlook upgrade from ICRA Limited on January 23, 2026, with the outlook revised from Stable to Positive. The rating agency reaffirmed the company's long-term rating at [ICRA] BB+ (Positive) and short-term rating at [ICRA] A4+ for total bank loan facilities worth Rs. 50.00 crores. The upgrade covers various banking facilities including term loans, cash credit, and letter of credit facilities primarily with ICICI Bank Limited.
 no imag found
12Nov 25
Bafna Pharmaceuticals Reports Revenue Growth and Profit Decline in Q2 FY2026
Bafna Pharmaceuticals Limited released its Q2 FY2026 results, showing a 2.44% increase in revenue to INR 3,546.82 crore, but a 7.79% decrease in net profit to INR 312.49 crore compared to Q2 FY2025. The company's total assets grew by 21.58% to INR 16,068.27 crore. The auditor's report highlighted issues with outstanding foreign currency receivables and an income tax refund adjustment under legal proceedings. Despite challenges, the company maintains steady revenue growth in the pharmaceutical sector.
 no imag found
12Aug 25
Bafna Pharmaceuticals Reports Strong Q1 Results, Announces Key Leadership Changes
Bafna Pharmaceuticals Limited reported strong Q1 FY2026 results with a net profit of ₹338.89 lakhs, compared to a loss in the previous year. Revenue from operations increased by 4.02% to ₹3,462.40 lakhs. The company announced its 30th AGM for September 19, 2025, and approved re-appointments of two Independent Directors and the CEO. The Nomination and Remuneration Committee was reconstituted. Bafna Pharmaceuticals also achieved the prescribed Minimum Public Shareholding and completed the sale of assets from its Madhavaram manufacturing unit.
 no imag found
Bafna Pharmaceuticals
136.02
-1.00
(-0.73%)
1 Year Returns:+83.76%
Industry Peers
Sun Pharmaceutical
1,620.40
(-3.55%)
Divis Laboratories
6,361.50
(-0.27%)
Torrent Pharmaceuticals
4,117.20
(-0.72%)
Dr Reddys Laboratories
1,317.10
(-1.04%)
Lupin
2,296.10
(-1.93%)
Cipla
1,295.00
(-0.83%)
Mankind Pharma
2,267.40
(-1.11%)
Zydus Life Science
927.40
(-2.00%)
Aurobindo Pharma
1,413.80
(-1.50%)
Glenmark Pharmaceuticals
2,299.50
(-1.52%)